TFFP cotización, noticias, gráficos, investigación bursátil, perfil.

 (TFFP) Bolsa Cotizaciones y resumen de noticias

TFF Pharmaceuticals

TFF Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It is focused on the development of inhaled dry powder drugs for the treatment of lung disorders.

TFF Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintains the price target from $20 to $20.

News

Upgrades

Price Target

Analyst Ratings

ACRS

HC Wainwright & Co. Upgrades Aclaris Therapeutics to Buy, Maintains Price Target to $20

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) with a Buy and maintains $18 price target.

Reiteration

VNDA

HC Wainwright & Co. Reiterates Buy on Vanda Pharma, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Buy and maintains $69 price target.

RYTM

HC Wainwright & Co. Reiterates Buy on Rhythm Pharmaceuticals, Maintains $69 Price Target

Market-Moving Exclusives

Exclusives

TELO

EXCLUSIVE: Telomir Pharmaceuticals Tells Benzinga Co. Confirms Copper-Binding Capabilities Of Telomir-1 And Expands Pipeline Into Wilson's Disease

Castellum, Inc. (NYSE-American: CTM) ("Castellum"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, announces that its <a href="https://www.globenewswire.com/Tracker?data=2uLrI8261QtiQmeyEX_gy6JpQ-moKeUMas7MX0KiELEefnH75OHV-JXUfPsv_zKI7gHoXxkBqsvA_eImOxN3D6G4PL5vSPCM60jU0LeJn-vqxAiMc5Hvq23f7HgN9H_j">subsidiary Specialty Systems, Inc.,</a> teaming with Castellum's other two subsidiaries <a href="https://www.globenewswire.com/Tracker?data=xuSy8FtCDO83pGRtqv3Bvd1mPpu7go0e-GbTqJOQfJpOv_sGIz-OJqLYw2ishXp8SNb4c4XnqbhR6CDFldnrtW6jI5X0Ly8kGJnXmWf_r7srd0t2OloOpVJX64Fh8CLU">Corvus Consulting, LLC</a> and <a href="https://www.globenewswire.com/Tracker?data=k8X5vM0eJAl01EJ9rJycnEmDk9yQVQVWU5kbUoIek9XS_3bxyu5GYFX64I44ybWTUYMcTU2iovmCpcKa02R-MD1goOgkN92qMYL4z1wzHMwClXsrY-NBB5mNeW7suWDSQclfL1E3M0ECNAUCnxh1Kg==">Global Technology and Management Resources, Inc.,</a> was awarded all four unrestricted domains upon which it submitted proposals. This award is in addition to the three small business domains the Castellum team has already been awarded on One Acquisition Solution for Integrated Services Plus ("OASIS+").
OASIS+ is a suite of government-wide, multi-award contracts designed to support federal agencies' procurement requirements for services-based solutions. With a potential ten-year performance period and no ceiling value, OASIS+ represents a significant opportunity for the Castellum team to expand its support to federal customers.

Government

Regulations

Castellum Secures Major Federal Contract Awards Through OASIS+ Program

GPUS

Hyperscale Data Secures Financing Agreement For Up To $25M In Series G Convertible Preferred Stock

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) with a Buy and maintains $7 price target.

RMTI

HC Wainwright & Co. Reiterates Buy on Rockwell Medical, Maintains $7 Price Target

On Monday, Telomir Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TELO#NASDAQ">TELO</a>) announced preclinical findings highlighting the copper-binding potential of its lead compound, Telomir-1, as a promising treatment for Wilson's disease and related disorders. The compound exhibits a binding affinity for copper ions, enabling precise regulation of copper metabolism and interacting with essential ions such as copper, iron, and zinc, the company said.
Recent preclinical studies by Recipharm and Smart Assays reveal Telomir-1's strong copper-binding affinity, enabling precise regulation of copper metabolism and interaction with essential ions.
According to the company, these findings position Telomir-1 as a potential breakthrough therapy for Wilson's disease, a rare disorder caused by ATP7B mutations leading to toxic copper buildup in vital organs.
Offering a safer alternative to current treatments, which have significant side effects and require lifelong adherence, Telomir-1 targets the disease's root cause and may qualify for orphan drug designation.
Telomir is also advancing Telomir-1's therapeutic potential in related areas, including Type 2 diabetes and age-related diseases.
The company is optimizing GMP-grade production for IND-enabling studies scheduled for second quarter of 2025, with an IND submission planned for the fourth quarter and first-in-human clinical trials expected by mid-2026. Efforts also include securing an INAD for pets and exploring Telomir-1's dual applications in human and veterinary medicine.
In line with its ethical practices, Telomir discontinued its osteoarthritis study in dogs after the safety phase due to concerns over inducing the condition. The company is now collaborating with a veterinary institution to design a study using elderly dogs naturally affected by osteoarthritis, advancing its INAD application for pets.
"As we look to 2025, Telomir remains dedicated to its mission," said Erez Aminov, Chairman and CEO. "We are pleased to have secured additional financing at a 20% premium with no warrants, providing the resources needed to continue advancing Telomir-1's development while creating value for our shareholders."
Price Action: TELO shares closed 14.10% higher at $5.18 on Friday.

Biotech

Health Care

General

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bms.com%2F&amp;esheet=54170253&amp;newsitemid=20241223250943&amp;lan=en-US&amp;anchor=Bristol+Myers+Squibb&amp;index=1&amp;md5=b5586a81e66ef03f03c233e8008cee0b">Bristol Myers Squibb</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) today announced that the European Commission (EC) has approved Opdivo&#xAE; (nivolumab) plus Yervoy&#xAE; (ipilimumab)for the first-line treatment of adult patients with microsatellite instability–high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer (mCRC).
"Colorectal cancer is the second leading cause of cancer death in Europe and patients are in need of new treatment options that delay disease progression. Approximately 5-7% of metastatic colorectal cancer patients have MSI-H/dMMR tumors and these patients are less likely to benefit from conventional chemotherapy and typically have poor prognosis outcomes," said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. "The EC's decision to approve Opdivo plus Yervoy represents a significant milestone for this patient population in the European Union and underscores our commitment to advancing treatment options."

Bristol Myers Squibb Wins EU Approval for New Colorectal Cancer Treatment

DA Davidson analyst Linda Bolton Weiser maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Buy and maintains $81 price target.

DA Davidson Maintains Buy on Estee Lauder Cos, Maintains $81 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates BrainsWay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWAY#NASDAQ">BWAY</a>) with a Buy and maintains $16 price target.

BWAY

HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Yi Chen initiates coverage on Sanara MedTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTI#NASDAQ">SMTI</a>) with a Buy rating and announces Price Target of $50.

Initiation

SMTI

HC Wainwright & Co. Initiates Coverage On Sanara MedTech with Buy Rating, Announces Price Target of $50

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $70 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $70 Price Target

HC Wainwright &amp; Co. analyst Andres Maldonado initiates coverage on enGene Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGN#NASDAQ">ENGN</a>) with a Buy rating and announces Price Target of $25.

ENGN

HC Wainwright & Co. Initiates Coverage On enGene Holdings with Buy Rating, Announces Price Target of $25

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024

NNVC

NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic

Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) today announced it has agreed to acquire Lexmark International, Inc., from Ninestar Corporation, PAG Asia Capital, and Shanghai Shouda Investment Centre in a deal valued at $1.5 billion, inclusive of assumed liabilities. This acquisition will strengthen the Xerox core print portfolio and build a broader global print and managed print services business better suited to meet the evolving needs of clients in the hybrid workplace.

Xerox to Acquire Lexmark in $1.5B Deal to Expand Print Services

On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities").
On December 20, 2024, Strawberry Fields REIT, Inc. (the "Company") entered into a Purchase and Sale Agreement with an unaffiliated seller with respect to six Healthcare Facilities located in Kansas (the "Facilities"). The purchase price for the Facilities is $24,000,000, payable at the closing.
The six facilities are comprised of five skilled nursing facilities and one assisted living facility with 354 licensed beds.
The facilities will be leased to Advena Living led by its founder Willie Novotny. The lease is for an initial 10-year period and includes two 5-year tenant options on a triple-net basis. Additionally, the lease will increase the Company's annual rents by $2.4 million and is subject to 3% annual increases.
The Company plans to purchase the facilities utilizing the Company's current working capital.

STRW

Strawberry Fields REIT To Acquire Six Kansas Healthcare Facilities for $24M

Zomedica Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZOM#NYSE">ZOM</a>) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of two new canine assays for the TRUFORMA In-Clinic Biosensor Testing Platform.
Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. Elevated NT-proBNP can be indicative of conditions such as congestive heart failure, assisting in the diagnosis and management of cardiac conditions in dogs. This test distinguishes cardiac from respiratory disease, identifies dogs at high risk of congestive heart failure, aids with chronic monitoring of dogs with myxomatous mitral valve degeneration all with reference lab accuracy.
"It is estimated that 1 in 10 dogs will experience heart disease in their life and unfortunately, most go undetected," said Dr. Kelli Puccio, a Professional Services Veterinarian for Zomedica. "Diagnosing and evaluating cardiac disease in our canine patients can be challenging. The TRUFORMA canine NT-proBNP assay facilitates the early detection of canine heart disease with the convenience of results in just a few minutes. This provides veterinarians with the ability to start treatments and schedule advanced diagnostic tests more quickly. Increasing our patients' quality of life earlier in the disease process." Additionally, this assay runs on either plasma or serum allowing more flexibility within a clinic's natural workflow.
 &nbsp;

Zomedica Launches New Canine Tests for Faster Heart Disease Detection

HC Wainwright &amp; Co. analyst Scott Buck maintains SoundHound AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) with a Buy and raises the price target from $8 to $26.

SOUN

HC Wainwright & Co. Maintains Buy on SoundHound AI, Raises Price Target to $26

<a href="https://www.globenewswire.com/Tracker?data=EvK5qYIL7c_16K93ZBIV_UFtMgPcLGgkcD7IshY3PCtSMlupDBlYnqtVSWF1N4Gw2XKatFqrvbqOxjYWR9wI5K4prfcV9UU3A5dR9pU3RKI=">Hyperscale Data, Inc.</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NYSE">GPUS</a>), a diversified holding company ("Hyperscale Data" or the "Company"), announced today that it has entered into a Securities Purchase Agreement (the "Agreement") providing for up to $25 million of financing (the "Financing") from Ault &amp; Company, Inc., a related party ("A&amp;C"). Pursuant to the Agreement, Hyperscale Data has agreed to issue and sell to A&amp;C up to $25 million in shares of Series G Convertible Preferred Stock (the "Preferred Shares"). The Preferred Shares will be senior to all other classes of preferred stock the Company has outstanding except with respect to the Series C Convertible Preferred Stock (the "Series C Preferred Stock"), with which it ranks in parity, as well as senior to the Company's Class A common stock ("Common Stock").
Each Preferred Share shall have a stated value of $1,000.00 per share and, upon stockholder approval, shall be convertible at the holder's option into shares of Common Stock at a conversion price equal to the greater of (i) $0.10 per share (the "Floor Price"), which Floor Price shall not, except for voting rights purposes, be adjusted for stock dividends, stock splits, stock combinations and other similar transactions and (ii) the lesser of (A) $6.74, or (B) a 5% premium to the closing sale price of the Common stock on the day immediately prior to the date of conversion (the "Conversion Price"). The Conversion Price will be subject to standard anti-dilution provisions in connection with any stock split, stock dividend, subdivision or similar reclassification of the Common Stock. The Preferred Stock also has "full ratchet" price protection in the event the Company should issue securities at a lower price than the Conversion Price. The Preferred Stock shall pay a dividend at an annual rate of 9.5%, which the Company may, during the first two years, pay in shares of Common Stock.
Further, A&amp;C will receive warrants ("Warrants") to purchase up to approximately 4.25 million shares of Common Stock, presuming that the full amount of the Preferred Shares is sold, exercisable for five years at $5.92 per share, subject to adjustment.
The proceeds from the Financing will be used for expansion of the MI data center to support infrastructure upgrades necessary to support the growing demands of high-performance computing services powering Artificial Intelligence solutions, repayment of outstanding indebtedness and general working capital purposes.

Hyperscale Data Secures $25M Financing to Boost AI Infrastructure Expansion

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on TFF Pharmaceuticals (TFFP – Research Report), reducing the price target to $4.00. J...

Buy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market Potential

TFF Pharmaceuticals, Cleveland Clinic advance influenza vaccine candidates into preclinical testing

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bottom-picking stocks to buy is one of the most difficult strategies in trading and investing. It is a direct antithesis to the adage, &ldquo;the trend is your friend, until it bends.&rdquo; While not for the faint of heart, bold investors are rewarded with the potential to be rewarded exponentially for the risk they are taking.&nbsp;



Bottom-picking is risky and not something you should always do as an investor. But if you were to do it, here&rsquo;s are a few ways to mitigate those risks.&nbsp;



For example, you can consider quality companies that are otherwise getting battered by sellers and are trading at their 52-week lows. So, today, I&rsquo;ll show you three stocks doing just that. To get my list, I used the filter below:



<ul><li>Stock trades near its 52-week low,</li>



<li>Minimum buy rating from analysts, and</li>



<li>Earnings and revenue growth in the last fiscal year.</li>
</ul>Getting buy-rated stocks means analysts see potential recovery in the future. The revenue growth metrics also indicate that the companies are doing relatively well.&nbsp;



This list represents the &ldquo;best three&rdquo; from the screen. I arranged it based on how far each stock is from its 52-week low, from highest to lowest. 



<h2>Microvast Holdings (MVST)</h2>



<a href="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst.png"><img width="300" height="222" src="https://investorplace.com/wp-content/uploads/2024/04/microvast-mvst-300x222.png" alt="A photo of a Microvast Holdings Inc (MVST) sign outside a building."></a>The growing demand for EVs has spotlighted companies like Microvast Holdings (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>). Microvast specializes in advanced battery technology, wherein it builds and develops battery systems used in utility-scale energy storage systems and electric commercial vehicles.&nbsp;



The company has created various proprietary technologies in the entire battery system. Microvast has a solid footprint globally and sells its products in three main regions: North and South America, EMEA, and Asia Pacific.&nbsp;



Microvast reported a <a href="https://ir.microvast.com/news-releases/news-release-details/microvast-reports-2023-financial-results">49.9% YOY revenue increase in FY&rsquo;23.</a> This excellent performance was primarily due to improvements in the EMEA and Asia Pacific regions. Specifically, EMEA is nearly operating at breakeven. Meanwhile, the business in Asia Pacific is entirely self-funding and profitable. The company is hoping for similar results in the Americas shortly.&nbsp;



In other good news, the company&rsquo;s net loss improved from $158.2 million in 2022 to $106.4 million in 2023. Microvast inches towards complete profitability and analysts have plenty of reasons to rate it as a strong buy. The stock is also trading 53.3% higher than its 52-week low. So, if you&rsquo;re looking for stocks to buy, don&rsquo;t miss out on MVST.



<h2>TFF Pharmaceuticals (TFFP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Biotech is full of baskets of opportunities waiting to be discovered. New firms race to be first to market. TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) is one of these contenders. The company develops the commercialization of patented Thin Film Freezing (TFF) by transforming medicine into a potent dry powder for better results.&nbsp;



TFF has two main drug candidates: Voriconazole Inhalation Powder (TFF VORI) and Tacrolimus Inhalation Powder (TFF TAC). Both products use its patented technology and help lung transplant and pulmonary aspergillosis patients.



A quick glance at TFF Pharma&rsquo;s <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-fourth-quarter-and-full-year-2023-financial-results/">FY&rsquo;23 results</a> reported revenues of $733,871, up from $495,805 in 2023. Harlan Weisman, M.D., the company&rsquo;s CEO, says, &ldquo;Over the last several months, we have made significant progress showing that our Thin Film Freezing technology can be successfully applied.&rdquo; Additionally, TFF TAC is heading to another positive catalyst, as the FDA is expected to provide feedback for its <a href="https://tffpharma.com/press_releases/tff-pharmaceuticals-reports-first-quarter-financial-results-and-provides-corporate-update/">Clinical Development Plan in Q2FY&rsquo;24</a>.



Though still operating at a loss, the company managed to minimize net losses to $21.2 million, a noticeable improvement from last year&rsquo;s loss of $31.8 million. The company&rsquo;s excellent prospects and growing financials make a strong case for considering it one of the best bargain stocks to buy.



But if you need something more, you&rsquo;d be happy to know analysts rate TFFP stock as <a href="https://www.nasdaq.com/market-activity/stocks/tffp/analyst-research">a Strong Buy</a>. Additionally, it&rsquo;s trading 25.3% higher from its 52-week low.&nbsp;



<h2>My Size (MYSZ)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/growthstocks_1600_02-300x169.jpg" alt="Hand of woman watering small plant in pot shaped like growing graph representing growth stocks. Sleeper Growth Stocks"><div>Source: Khakimullin Aleksandr / Shutterstock</div></div>Formerly known as Knowledgetree Ventures, My Size (NASDAQ:<a href="https://investorplace.com/stock-quotes/mysz-stock-quote/">MYSZ</a>) is an eCommerce platform that lets users build their online profile and store their personal measurements, which will allow buyers to make purchases to retailers using their data and get the right fit.&nbsp;



While this may sound simple enough, the company uses a <a href="https://mysizeid.com/reports/naiz-fit-a-my-size-inc-company-unveils-groundbreaking-generative-ai-strategies-to-revolutionize-fashion-tech/">groundbreaking generative AI tool</a> that lets users work with specialized language models to help customers receive tailored product reals that suit their needs. In addition, the company&rsquo;s AI provides virtual try-ons that allow customers to mix and match garments and visually show how pairs work together.&nbsp;



My Size reported improvements in FY&rsquo;23. Revenue hit $7 million, up from $4.5 million last year. Meanwhile, the bottom line ended at a $6.38 million loss compared to last year&rsquo;s $8.31 million loss. Unfortunately, <a href="https://investorplace.com/earning-results/2024/04/mysz-stock-earnings-my-size-for-q4-of-2023/">some financial metrics missed estimates</a> for Q4 and the whole year, and the stock has taken a beating ever since.&nbsp;



Still, MYSZ stock is rated as a <a href="https://www.nasdaq.com/market-activity/stocks/mysz/analyst-research">Strong Buy</a>, trading 7.6% higher than its 52-week low. More adventurous investors looking for stocks to buy might see this as an opportunity.&nbsp;



On the date of publication, Rick Orford did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Rick Orford is a Wall Street Journal best-selling author, investor, influencer, and mentor. His work has appeared in the most authoritative publications, including Good Morning America, Washington Post, Yahoo Finance, MSN, Business Insider, NBC, FOX, CBS, and ABC News.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/3-52-week-low-losers-ready-to-become-big-time-stock-winners/">3 52-Week-Low Losers Ready to Become Big-Time Stock Winners</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 52-Week-Low Losers Ready to Become Big-Time Stock Winners

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
TFF Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tffp-stock-quote/">TFFP</a>) just reported results for the second quarter of 2024.<ul><li>TFF Pharmaceuticals reported earnings per share of -$1.22. This was above the analyst estimate for EPS of -$1.78.</li><li>The company reported revenue of $650,222.</li><li>This was 766.96% better than the analyst estimate for revenue of $75,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/tffp-stock-earnings-tff-pharmaceuticals-for-q2-of-2024/">TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

TFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

TFF Pharmaceuticals GAAP EPS of -$1.22 misses by $0.41, revenue of $0.65M beats by $0.5M

TFF Pharmaceuticals enters pact for dry powder mRNA-based Covid treatment

TFF Pharmaceuticals to wind down operations

TFF Pharmaceuticals ( ($TFFP) ) has provided an announcement. TFF Pharmaceuticals, Inc. is set to dissolve following its board's approval of a liqu...

TFF Pharmaceuticals to Dissolve and Liquidate Assets

16:45 EST TFF Pharmaceuticals (TFFP) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financia...

TFF Pharmaceuticals trading resumes

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

CYCN

EYEN

MVST

MYSZ

TFFP

Press Releases

TFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical Testing

TFF Pharmaceuticals Provides Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical Program for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing Opportunities

TFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Earnings

TFF Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update

TFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

TFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal Immunization

TFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVID

TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

TFF Pharmaceuticals Announces It Will Wind Down Operations

Roth MKM

HC Wainwright & Co.

JonesTrading

B. Riley Securities

Learn About Cryptocurrency

acf/sidebar-related-posts

Learn about this leading blockchain platform that supports decentralized applications and smart contracts.

What is Ethereum?

Earning interest on your Ethereum is a great way to grow your cryptocurrency holdings. Find out how to earn interest on your Ethereum in 4 easy steps.

How to Earn Interest on Ethereum

Discover the 10 best cryptocurrencies to invest in for November 2024. Stay ahead in the crypto market with our expert insights and analysis! Learn more now!

10 Best Cryptocurrencies to Invest In for December 2024

10 Best Cryptocurrencies to Invest in for November 2024

Discover the best altcoins to invest in for high potential returns. Our top altcoin picks include Ethereum, Solana, Ripple, Dogecoin, Toncoin.

Top 10 Best Altcoins • Benzinga Crypto

10 Best Altcoins in November 2024

Top Cryptocurrency News

acf/news-feed

Cryptocurrency

Markets

Movers

Trading Ideas

$BTC

$DOGE

$ETH

Bitcoin, Ethereum, Dogecoin Lose Sheen Ahead Of Holidays But Top Analyst Points To This Indicator, Says BTC Will Hit A Top Above $168K

Analyst Color

Equities

IBIT

MSTR

MicroStrategy Stock Declines Over 14% Amid Heightened Volatility Over S&P 500 Inclusion Concerns: Here's What Is Happening

$SHIB

Analyst Bullish on Shiba Inu, Sees 235% Surge Despite Recent Fall

Scaramucci Defends MicroStrategy's Bitcoin Strategy, Predicts Long-Term Crypto Growth

Politics

Dogecoin Turns Green As Trump Appoints Loyalist Katie Miller To The Department Of Government Efficiency

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	1

Apertura	-
Cierre	-
Volumen / Prom.	- / -
Rango diario	- - -
Rango de 52 semanas	- - -
Capitalización bursátil	-
Ratio PER	-
Rentabilidad por dividendo	-
Exchange
RSI	0
Interés en corto	-
Días para cubrir	1

Comments

(TFFP) Previsión

(TFFP) Bolsa Cotizaciones y resumen de noticias

Noticias recientes

Finanzas

Calificación de analistas

Comparar

PREGUNTAS FRECUENTES

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación